These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Improving efficiency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice. Bhandari S; Naudeer S J Eval Clin Pract; 2008 Dec; 14(6):996-1001. PubMed ID: 18785894 [TBL] [Abstract][Full Text] [Related]
24. Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO). Saltissi D; Sauvage D; Westhuyzen J Clin Nephrol; 1998 Jan; 49(1):45-8. PubMed ID: 9491286 [TBL] [Abstract][Full Text] [Related]
25. A novel short-course regimen of intramuscular iron therapy for anaemic pregnant women. Thirunavukkarasu S; Bhandary A Trop Doct; 2009 Oct; 39(4):227-8. PubMed ID: 19671779 [TBL] [Abstract][Full Text] [Related]
27. Oral and parenteral iron. Med Lett Drugs Ther; 1969 Mar; 11(5):18-9. PubMed ID: 5813815 [No Abstract] [Full Text] [Related]
28. Severe intravascular haemolysis and acute renal failure following intravenous administration of iron dextran. Buus NH; Jensen JD Nephrol Dial Transplant; 2007 Feb; 22(2):661-2. PubMed ID: 16968716 [No Abstract] [Full Text] [Related]
29. The safety of intravenous iron dextran (Dexferrum) during hemodialysis in patients with end stage renal disease. Hood SA; O'Brien M; Higgins R Nephrol Nurs J; 2000 Feb; 27(1):41-2. PubMed ID: 10852689 [TBL] [Abstract][Full Text] [Related]
30. How safe is it to give parenteral iron to a patient with rheumatoid arthritis (RA) and iron deficiency anaemia? Merry P; Kidd B; Blake DR Br J Rheumatol; 1989 Feb; 28(1):22. PubMed ID: 2917225 [No Abstract] [Full Text] [Related]
31. Accelerated total dose infusion of low molecular weight iron dextran is safe and efficacious in chronic kidney disease patients. Sinha S; Chiu D; Peebles G; Swoboda P; Kolakkat S; Lamerton E; Fenwick S; Bhandari S; Kalra PA QJM; 2011 Mar; 104(3):221-30. PubMed ID: 20956457 [TBL] [Abstract][Full Text] [Related]
32. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Sav T; Tokgoz B; Sipahioglu MH; Deveci M; Sari I; Oymak O; Utas C Ren Fail; 2007; 29(4):423-6. PubMed ID: 17497463 [TBL] [Abstract][Full Text] [Related]
33. Safe administration of iron dextran to a patient who reacted to the test dose. Monaghan MS; Glasco G; St John G; Bradsher RW; Olsen KM South Med J; 1994 Oct; 87(10):1010-2. PubMed ID: 7939912 [TBL] [Abstract][Full Text] [Related]
34. Comparative therapeutic study of T.D.I. and I.M. injections of iron dextran complex in anaemia. Kanakaraddi VP; Hoskatti CG; Nadig VS; Patil CK; Maiya M J Assoc Physicians India; 1973 Oct; 21(10):849-53. PubMed ID: 4793273 [No Abstract] [Full Text] [Related]
35. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study. Schröder O; Mickisch O; Seidler U; de Weerth A; Dignass AU; Herfarth H; Reinshagen M; Schreiber S; Junge U; Schrott M; Stein J Am J Gastroenterol; 2005 Nov; 100(11):2503-9. PubMed ID: 16279906 [TBL] [Abstract][Full Text] [Related]
36. [Safety aspects of parenteral iron supplementation therapies in patients with chronic kidney disease]. Potthoff SA; Münch HG Dtsch Med Wochenschr; 2013 Jun; 138(24):1312-7. PubMed ID: 23737117 [TBL] [Abstract][Full Text] [Related]
37. Treatment of iron deficiency. Callender ST Clin Haematol; 1982 Jun; 11(2):327-38. PubMed ID: 7042154 [No Abstract] [Full Text] [Related]
38. Intravenous iron in a primary-care clinic. Maslovsky I Am J Hematol; 2005 Apr; 78(4):261-4. PubMed ID: 15795917 [TBL] [Abstract][Full Text] [Related]